Skip to main content
NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.61%GBPCHF+0.51%AUDCHF+0.47%NZDCHF+0.45%GBPTRY+0.41%USDCAD-0.41%EURCAD-0.36%CADJPY+0.34%AUDSGD+0.32%GBPHKD+0.32%GBPUSD+0.31%NZDSGD+0.31%NZDUSD+0.29%GBPMXN-0.28%AUDUSD+0.28%USDTRY+0.27%EURCHF+0.25%GBPJPY+0.25%CHFJPY-0.24%NZDMXN+0.23%USDNOK-0.23%EURGBP-0.23%AUDJPY+0.22%NZDJPY+0.21%USDZAR-0.21%GBPSGD+0.20%USDCHF+0.19%EURAUD-0.19%EURNZD-0.17%NOKJPY+0.17%USDSEK-0.17%CHFSGD+0.17%AUDDKK+0.16%USDILS+0.16%EURSGD+0.16%NZDCAD-0.16%USDPLN-0.16%AUDCAD-0.13%EURNOK-0.13%CHFNOK-0.12%SGDJPY-0.12%EURZAR-0.11%EURHKD+0.10%USDDKK-0.10%PLNJPY+0.10%GBPCAD-0.09%EURCNH+0.08%GBPZAR-0.08%EURUSD+0.07%EURSEK-0.06%CHFSEK-0.06%USDSGD+0.06%EURPLN-0.06%USDJPY-0.05%USDTHB+0.05%GBPAUD+0.05%USDCOP-0.04%AUDNOK+0.04%GBPNZD+0.03%USDCNH-0.02%USDMXN-0.02%EURJPY+0.02%AUDNZD+0.02%EURCZK+0.01%USDHKD+0.01%EURDKK0.00%HG1+0.79%COTTON+0.75%XNGUSD+0.42%S1+0.42%W1-0.28%XAGUSD+0.26%GAGUSD+0.25%UKOIL-0.19%USOIL-0.15%XAUUSD+0.13%GAUUSD+0.13%XPTUSD+0.08%BTCUSD+2.42%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.82%DOGEUSD+14.12%XMRUSDT+5.80%LINKUSD+13.42%XLMUSD+0.34%BCHUSDT+5.78%LTCUSD+9.66%UNIUSD+7.79%SUIUSD+3.65%HBARUSDT+0.48%TONUSD+26.15%TAOUSDT+3.98%AAVEUSD+3.78%DOTUSDT+0.06%ICPUSDT+0.82%ONDOUSDT+0.53%WLDUSDT+0.17%ARBUSDT+6.90%JUPUSDT+0.62%ATOMUSDT+1.84%INJUSDT+13.93%STXUSDT+5.78%FETUSDT+3.16%TIAUSDT+9.38%PYTHUSDT-0.47%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+19.70%GRTUSDT+4.03%IOTAUSDT+1.15%WIFUSDT+2.70%AXSUSDT-1.74%POLUSDT+2.83%FARTCOINUSDT+0.81%EOSUSDT+2.46%DYDXUSDT+3.59%GALAUSDT-1.87%ORDIUSDT+0.06%RONINUSDT-3.42%NOTUSDT+1.21%NVDA+0.21%AAPL-0.23%GOOGL+0.30%MSFT-0.42%AMZN-0.29%TSM+0.17%SPCX-4.21%META+0.03%AVGO+0.73%TSLA-0.15%BRK-B+0.61%SKHY-3.19%LLY-1.36%MU+0.27%AMD+1.90%WMT-0.71%JPM-0.86%V+1.74%XOM+1.12%ASMLa-4.20%JNJ-5.73%MA+1.63%INTC+1.44%0700.HK-0.03%ABBV-2.40%1398.HK-1.41%CSCO-0.23%CVX+1.27%COST-0.50%ORCL+4.23%KO+0.36%BAC-1.14%DELL-0.72%LRCX-2.73%AMAT-6.69%PG-0.10%AP2d-8.45%CAT-3.33%UNH-0.20%3988.HK-1.16%1816.HK-25.11%0005.HK-1.09%HSBA.L+0.17%0857.HK+0.29%GE-0.33%PM-1.34%0939.HK-1.63%1288.HK-2.19%MS-1.78%NFLX-0.21%CADCHF+0.61%GBPCHF+0.51%AUDCHF+0.47%NZDCHF+0.45%GBPTRY+0.41%USDCAD-0.41%EURCAD-0.36%CADJPY+0.34%AUDSGD+0.32%GBPHKD+0.32%GBPUSD+0.31%NZDSGD+0.31%NZDUSD+0.29%GBPMXN-0.28%AUDUSD+0.28%USDTRY+0.27%EURCHF+0.25%GBPJPY+0.25%CHFJPY-0.24%NZDMXN+0.23%USDNOK-0.23%EURGBP-0.23%AUDJPY+0.22%NZDJPY+0.21%USDZAR-0.21%GBPSGD+0.20%USDCHF+0.19%EURAUD-0.19%EURNZD-0.17%NOKJPY+0.17%USDSEK-0.17%CHFSGD+0.17%AUDDKK+0.16%USDILS+0.16%EURSGD+0.16%NZDCAD-0.16%USDPLN-0.16%AUDCAD-0.13%EURNOK-0.13%CHFNOK-0.12%SGDJPY-0.12%EURZAR-0.11%EURHKD+0.10%USDDKK-0.10%PLNJPY+0.10%GBPCAD-0.09%EURCNH+0.08%GBPZAR-0.08%EURUSD+0.07%EURSEK-0.06%CHFSEK-0.06%USDSGD+0.06%EURPLN-0.06%USDJPY-0.05%USDTHB+0.05%GBPAUD+0.05%USDCOP-0.04%AUDNOK+0.04%GBPNZD+0.03%USDCNH-0.02%USDMXN-0.02%EURJPY+0.02%AUDNZD+0.02%EURCZK+0.01%USDHKD+0.01%EURDKK0.00%HG1+0.79%COTTON+0.75%XNGUSD+0.42%S1+0.42%W1-0.28%XAGUSD+0.26%GAGUSD+0.25%UKOIL-0.19%USOIL-0.15%XAUUSD+0.13%GAUUSD+0.13%XPTUSD+0.08%BTCUSD+2.42%ETHUSD+17.67%USDTUSD+0.02%XRPUSD+11.86%SOLUSD+12.05%TRXUSDT+0.77%ZECUSDT+8.82%DOGEUSD+14.12%XMRUSDT+5.80%LINKUSD+13.42%XLMUSD+0.34%BCHUSDT+5.78%LTCUSD+9.66%UNIUSD+7.79%SUIUSD+3.65%HBARUSDT+0.48%TONUSD+26.15%TAOUSDT+3.98%AAVEUSD+3.78%DOTUSDT+0.06%ICPUSDT+0.82%ONDOUSDT+0.53%WLDUSDT+0.17%ARBUSDT+6.90%JUPUSDT+0.62%ATOMUSDT+1.84%INJUSDT+13.93%STXUSDT+5.78%FETUSDT+3.16%TIAUSDT+9.38%PYTHUSDT-0.47%SEIUSDT+4.57%IMXUSDT+0.63%OPUSDT+19.70%GRTUSDT+4.03%IOTAUSDT+1.15%WIFUSDT+2.70%AXSUSDT-1.74%POLUSDT+2.83%FARTCOINUSDT+0.81%EOSUSDT+2.46%DYDXUSDT+3.59%GALAUSDT-1.87%ORDIUSDT+0.06%RONINUSDT-3.42%NOTUSDT+1.21%
AL

Aldeyra The (ALDX)

NASDAQ • Healthcare

$0.89
-$0 (-0.7%)
Market closed

Last close at October 13, 2026 at 20:00 UTC

Open$0.89
Day Range$0.87 - $0.91
Avg. Volume (3M)1.8M
Market Cap$54.2M
52 Week Range
$0.86$5.93
Next EarningsIn 21 daysNov 4, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$23M
EPS (TTM)
-$0.39
ROA (TTM)
-48.49%
Current Ratio
4.91

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+21.4%Q1 2026-$0.11
+53.8%Q2 2026-$0.06
-2.9%Q3 2026-$0.09
Next

Nov 4

in 21 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -2.9%

Aldeyra The’s bottom line improved year over year but EPS of -$0.090 trailed the -$0.087 estimate (difference -$0.003) based on preliminary results for the second fiscal quarter of 2026 that it reported on August 6, 2026. Net income narrowed to a loss of about $5.5 million, up ~44% from a loss of roughly $9.8 million a year ago, alongside EPS improving ~44% from -$0.160. Operating income came in at a loss of about $5.9 million, and the company posted negative operating cash flow of roughly $4.6 million for the quarter. For the next period, consensus calls for EPS of -$0.110 on revenue of $2.5 million.

Next report — what to expect

Aldeyra The (ALDX) reports next on November 4, 2026. Wall Street is looking for EPS of -$0.11 on revenue of $2.5 million. Traders will be watching how results compare with those benchmarks, with ALDX having beaten EPS estimates in 5 of its 8 most recent quarters.

View full earnings history

About Aldeyra The

Aldeyra The is a small-cap biotechnology company listed on NASDAQ under ALDX that discovers and develops therapies for immune-mediated diseases. The pipeline centers on inflammation-focused drug candidates spanning late-stage, mid-stage, and preclinical programs, with work rooted in both RASP modulation and a dihydrofolate reductase inhibitor approach.

Name
Aldeyra The
CEO
Todd C. Brady
Website
www.aldeyra.com
Industry
Healthcare
Year Founded
2004
Employees
6

Today's Snapshot

AI-generated

ALDX closed 0.7% lower at 0.90, in line with a weaker sector. Trading was lighter than usual, with volume about half of its usual level.

Trading Volume

Below 10d avg (2.6M)

1.4M

vs S&P 500 Today

Underperforming Market

-0.64%

Updated: October 13, 2026 at 20:26 UTC

Technical Indicators

2 Buy0 Neutral6 Sell
ALDX is tilted decisively negative: ADX shows a strong downward trend, price is substantially below short-, medium- and long-term moving averages, and MACD is negative despite some oversold readings on RSI and stochastic. Volume trends are heavily negative on OBV, reflecting sustained distribution, while ATR is high relative to the stock, indicating elevated volatility. Those factors, combined with momentum leaning lower overall, support the strong sell classification. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$1.01 - $2.62
    Sell
  • RSI (14)29.30
    Buy
  • Stochastic %K (14, 3, 3)7.86
    Buy
  • MACD Level (12, 26)-0.15
    Sell

Peers & Related Assets

ANROAlto Neuroscience, Inc.
CADLCandel Therapeutics, Inc.
SLNSilence Therapeutics plc
KYTXKyverna Therapeutics, Inc.
CTNMContineum Therapeutics, Inc.
ACIUAC Immune S.A.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.